| Name | Azithromycin |
| Description | Azithromycin (CP 62993) is a macrolide antibiotic that primarily targets the 50S subunit of bacterial ribosomes. Azithromycin is commonly used in studies of bacterial infections. |
| Cell Research | THP-1 cells (106 cells in 1 mL RPMI medium, without antibiotics, growth factors or serum) are seeded in each well of 24-well plates and allowed to settle for 1 hour. Next, 50 μL of the test compound is added followed by 50 μL of LPS (final concentration of 10 μg/mL). After 24h (37°C and 5% CO2) the supernatants and cell pellets are collected (1200 rpm, 5 min). THP-1 cell viability is tested using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT). MTT is dissolved at 2 mg/mL in PBS and aliquots are stored at -20°C. The MTT assay is performed according to the suppliers instructions. Absorbance of MTT converted into formazan is measured at a wavelength of 570 nm with background subtraction at 630 nm. |
| In vitro | METHODS: HeLa, MG-63 and Osteoblast cells were treated with Azithromycin (0-400 μg/mL) for 48 hours, and MTT assay was used to detect the inhibition of cell metabolic activity.
RESULTS: Azithromycin inhibited the growth of HeLa (IC50=160 μM), MG-63 (IC50=180 μM) and Osteoblast (IC50=160 μM) cells. [1] |
| In vivo | METHODS: To study the effect of Azithromycin on asthma, a mouse model of asthma attack was treated with Azithromycin (50 mg/kg).
RESULTS: Azithromycin had no effect on bronchoalveolar lavage inflammatory parameters and LDH levels in a mouse model of asthma exacerbation. Azithromycin did not induce general inflammatory parameters or LDH release in a mouse model of asthma exacerbations and increased expression of an interferon-stimulated gene and the pattern recognition receptor MDA5 but not RIG-I in mice with asthma exacerbations. [2] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 18.33 mg/mL (24.47 mM), Sonication is recommended.
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (2.67 mM), Sonication is recommended.
Ethanol : 74.9 mg/mL (100 mM), Sonication is recommended.
|
| Keywords | XZ450 | XZ 450 | protein synthesis | Inhibitor | inhibit | CP-62993 | CP62993 | Bacterial | Azithromycin | Autophagy | Antibiotic |
| Inhibitors Related | Neomycin sulfate | Aceglutamide | Cysteamine hydrochloride | Adipic dihydrazide | Sulfamethoxazole sodium | Terbinafine hydrochloride | Hydroxychloroquine | Metronidazole | 2-Amino-2-methyl-1-propanol | Fenpyroximate | Paeonol | BES |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Bioactive Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Microbial Natural Product Library | FDA-Approved Drug Library | Natural Product Library for HTS | Anti-Cancer Approved Drug Library | Immunology/Inflammation Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library |
United States
